I. Why We Need New Approaches to Treating MS – Fred D. Lublin, MD
II. The Science of BTK Inhibitors: Adaptive and Innate Immunity
– Benjamin M. Greenberg, MD, MHS
III. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Mark S. Freedman, MD
IV. Faculty Panel Discussion: Treatment Strategies for the Application of BTK-Inhibitor Therapeutics to Optimize MS Patient Outcomes – Fred D. Lublin & Faculty
JOINT ACCREDITATION STATEMENT
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION STATEMENTS
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 Credits TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Sanofi Genzyme.
*This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.